Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator

Journal of Clinical Pharmacology

Volumn 49, Issue 1, 2009, Pages 50-62

  Rohatagi, Shashank ^a   Zahir, Hamim ^a   Moberly, James B ^a   Truitt, Kenneth E ^a   Inaba, Shin Ichi ^a   Shimozato, Takaichi ^a   Carrothers, T J ^b  

^a DAIICHI SANKYO INC   (United States)

^b Pharsight   (United States)

Author keywords

CD4; CS 0777; Dose optimization; Lymphocytes; PK PD; Sphingosine 1 phosphate receptor

Indexed keywords

CS 0777; IMMUNOMODULATING AGENT; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; HUMAN; LYMPHOCYTE COUNT; MALE; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PRODRUGS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; YOUNG ADULT;

EID: 58149186692     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008325672     Document Type: Article

References (36)

1. Pyne S., Pyne NJ Sphingosine 1-phosphate signaling in mammalian cells. Biochem J. 2000 ; 349: 385-402.
2. Hla T., Lee M. -J, Ancellin N., Paik JH, Kluk MJ Lysophospholipids- receptor revelations. Science. 2001 ; 294: 1875-1878.
3. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nature Rev Mol Cell Biol. 2003 ; 4: 397-407.
4. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Devel Biol. 2004 ; 15: 513-520.
5. Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest. 2004 ; 114: 1531-1537.
6. Cyster JG Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Ann Rev Immunol. 2005 ; 23: 127-159.
7. Rosen H., Goetzl EJ Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nature Rev Immunol. 2005 ; 5: 560-570.
8. Ogretmen B. Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett. 2006 ; 580: 5467-5476.
9. Allende ML, Dreier JL, Mandala S., Proia RL Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem. 2004 ; 279: 15396-15401.
10. Matloubian M., Lo CG, Cinamon G., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004 ; 427: 355-360.
11. Mandala S., Hajdu R., Bergstrom J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002 ; 296: 346-349.
12. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005 ; 108: 308-319.
13. Brinkmann V., Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 ; 277: 21453-21457.
14. Brinkmann V., Pinschewer DD, Feng L., Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation. 2001 ; 72: 764-769.
15. Fujino M., Funeshima N., Kitazawa Y., et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003 ; 305: 70-77.
16. Webb M., Tham C-S., Lin F-F., et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol. 2004 ; 153: 108-121.
17. Kataoka H., Sugahara K., Shimano K., et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005 ; 2: 439-448.
18. Budde K., Schmouder RL, Brunkhorst R., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002 ; 13: 1073-1083.
19. Tedesco-Silva H., Mourad G., Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2a study in de novo renal transplantation. Transplantation. 2005 ; 79: 1553-1560.
20. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 ; 355: 1124-1140.
21. Böhler T., Waiser J., Schuetz M., Neumayer HH, Budde K. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant. 2004 ; 19 (3). 702-713.
22. Budde K., Schmouder RL, Nashan B., et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant. 2003 ; 3 (7). 846-854.
23. Magee MH, Blum RA, Lates CD, Jusko WJ Pharmacokinetic/ pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol. 2002 ; 53: 474-484.
24. Mullmann H., Hochhaus G., Rohatagi S., Barth JU, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methyiprednisolone and prednisolone. Pharm Res. 1995 ; 12: 1096-1110.
25. Rohatagi S., Hochhaus G., Mollmann H., et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995 ; 35: 1187-1193.
26. Li H., Meno-Tetang GM, Chiba K., et al. Pharmacokinetics and cell trafficking dynamics of (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther. 2002 ; 301: 519-526.
27. Wald JA, Salazar DE, Chen HY, Jusko WJ Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm. 1991 ; 19 (5). 521-536.
28. Beal SL, Sheiner LB, eds. NONMEM Users Guides. Hanover, MD: Globomax LLC ; 1992.
29. Bohler T., Schutz M., Budde K., Neumayer HH, Waiser J. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. Int Immunopharmacol. 2007 ; 7 (1). 88-95.
30. AIDS Education and Training Centers. Clinical Manual for Management of HIV-Infected Adult. 2006 ed. Available at: http://www.aidsetc.org/aidsetc?page= cm-00-00. Accessed October 21, 2007.
31. Zohar S., Chevret S. Recent developments in adaptive designs for phase I/II dose-finding studies. J Biopharm Stat. 2007 ; 17 (6). 1071-1083.
32. Hauser SL, Waubant E., Arnold DL, Vollmer T., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688.
33. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006 ; 3 (1). 57-71.
34. Wang L., Cui L. Seamless phase II/III combination study through response adaptive randomization. J Biopharm Stat. 2007 ; 17 (6). 1177-1187.
35. Lavori PW, Dawson R. Improving the efficiency of estimation in randomized trials of adaptive treatment strategies. Clin Trials. 2007 ; 4 (4). 297-308.
36. Rogatko A., Schoeneck D., Jonas W., Tighiouart M., Khuri FR, Porter A. Translation of innovative designs into phase I trials. J Clin Oncol. 2007 ; 25 (31). 4982-4986.